HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Richard C Bates Selected Research

STA 9090

6/2015The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
1/2015The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.
8/2014The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
3/2014Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
2/2014Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
1/2014Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
12/2013A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.
4/2013Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
4/2011Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Richard C Bates Research Topics

Disease

16Neoplasms (Cancer)
06/2019 - 05/2003
6Colorectal Neoplasms (Colorectal Cancer)
08/2014 - 02/2005
6Carcinoma (Carcinomatosis)
12/2005 - 05/2003
3Neoplasm Metastasis (Metastasis)
01/2014 - 12/2005
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2015 - 04/2013
1Lymphadenopathy
01/2015
1Splenomegaly
01/2015
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2015
1Disease Progression
01/2015
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2014
1Carcinogenesis
03/2014
1Melanoma (Melanoma, Malignant)
02/2014
1Triple Negative Breast Neoplasms
01/2014
1Toxic Optic Neuropathy
12/2013
1Vision Disorders (Hemeralopia)
12/2013
1Leukemia
04/2011
1Lymphatic Metastasis
12/2005

Drug/Important Bio-Agent (IBA)

9STA 9090IBA
06/2015 - 04/2011
4Transforming Growth Factor beta (TGF-beta)IBA
01/2007 - 05/2003
3Heat-Shock Proteins (Heat-Shock Protein)IBA
08/2014 - 12/2013
3IntegrinsIBA
01/2007 - 02/2005
3integrin alphavbeta6IBA
12/2005 - 02/2005
2AntigensIBA
06/2019 - 12/2005
2Pharmaceutical PreparationsIBA
11/2015 - 07/2014
2Molecular Chaperones (Chaperone, Molecular)IBA
07/2014 - 04/2013
2Proteins (Proteins, Gene)FDA Link
03/2014 - 04/2011
2CytokinesIBA
10/2004 - 05/2003
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2004 - 05/2003
1Immunoconjugates (Immunoconjugate)IBA
06/2019
1Cytotoxins (Cytolysins)IBA
06/2019
1Monoclonal AntibodiesIBA
06/2019
1STA-12-8666IBA
11/2015
1Irinotecan (Camptosar)FDA LinkGeneric
11/2015
1Topoisomerase I InhibitorsIBA
11/2015
1Gefitinib (Iressa)FDA Link
06/2015
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2015
1ErbB Receptors (EGF Receptor)IBA
06/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2015
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2015
1Fluorouracil (Carac)FDA LinkGeneric
08/2014
1Capecitabine (Xeloda)FDA Link
08/2014
1ProdrugsIBA
08/2014
1Oncogene Proteins (Oncogene Protein)IBA
05/2014
1TAK 733IBA
02/2014
1Proto-Oncogene Proteins B-rafIBA
02/2014
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2014
1VemurafenibIBA
02/2014
117- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA
12/2013
1Retinaldehyde (Retinal)IBA
12/2013
15- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA
12/2013
1tanespimycin (17AAG)IBA
12/2013
1Phosphotransferases (Kinase)IBA
04/2013
1CrizotinibIBA
04/2013
1Anaplastic Lymphoma KinaseIBA
04/2013
1Janus KinasesIBA
04/2011
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2007
1CateninsIBA
12/2005
1Cadherins (E-Cadherin)IBA
12/2005
1Delta CateninIBA
12/2005
1Indicators and Reagents (Reagents)IBA
02/2005
1Fibronectins (Fibronectin)IBA
02/2005
1integrin beta6IBA
02/2005
1Transcription Factors (Transcription Factor)IBA
10/2004
1Interleukin-8 (Interleukin 8)IBA
10/2004
1NF-kappa B (NF-kB)IBA
10/2004
1ChemokinesIBA
10/2004
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2004
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2004
1Integrin alpha6beta4IBA
04/2004
1Transforming Growth Factor beta1 (TGF beta 1)IBA
05/2003

Therapy/Procedure

8Therapeutics
06/2019 - 04/2004
1Drug Therapy (Chemotherapy)
01/2014